BioSpace News Archive

Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, will present at the upcoming 2022 BIO CEO & Investor Conference, which will be held in New York City on February 14-17, 2022.

Advarra announced that it has expanded its Early Phase Center of Excellence to include institutional review board review capabilities for cosmetics research.

The orthobiologics market has been projected to experience various growth avenues in the foreseeable years.

Rockwell Medical, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock.

Inventiva reported its cash position as of December 31, 2021, and its 2021 full-year revenues.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors.

Vera Therapeutics, Inc. (“Vera”), today announced the closing of its public offering of 5,742,026 shares of its Class A common stock at a price to the public of $15.00 per share, which includes the full exercise of the underwriters’ option to purchase up to 748,959 additional shares.

Clearside Biomedical, Inc. announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector® were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12, 2022.

Treace Medical Concepts, Inc., a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus, announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Thursday, March 3, 2022.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces its operating results for the first quarter of fiscal year 2022 ended December 31, 2021.